Washington University Eye Center — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$58,492	10
2022	Research	$38,519	7
2021	Research	$29,982	13
2020	Research	$95,733	14
2019	Research	$469,387	42

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $324,176 46 payments
Ipsen Biopharmaceuticals, Inc $124,387 7 payments
Acerta Pharma LLC $109,092 8 payments
AstraZeneca UK Limited $68,835 9 payments
GlaxoSmithKline, LLC. $38,000 11 payments
Ipsen Bioscience Inc $18,355 4 payments
AstraZeneca AB $9,267 1 payment

Studies the money was for Research payments · program years 2019–2025

A Pilot Study ofLiposomal IrinotecanPlus 5-FU LVCombinedWithParicalcitol in PatientsWithAdvanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy $107,066 1 payment
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $94,833 10 payments
An Open Label, Multi Drug, Biomarker Directed, Multi Centre Phase II Umbrella Study in Patients with Non Small Cell Lung Cancer, who Progressed on an anti PD 1/PD L1 Containing Therapy, HUDSON $49,075 3 payments
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) $38,183 1 payment
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis $38,000 11 payments
A Phase I Multicenter Study of Immunotherapy in Combination with Chemoradiation in Patients with Advanced Solid Tumors (CLOVER) $30,616 2 payments
A Phase II Randomized Open Label Multi Center Global Study of MEDI4736 Monotherapy Tremelimumab Monotherapy and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck SCCHN $29,102 2 payments
This Phase I study is primarily designed to evaluate the safety and tolerability of AZD2811 at increasing doses in patients with advanced solid tumours and for whom no standard of care exists The study will be conducted in two parts a dose escalation phase Part A and a dose expansion phase Part B $28,990 1 payment
A Phase III Randomized Open Label Multi Center Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small Cell Lung Cancer NSCLC MYSTIC $23,550 1 payment
A Phase 2 Proof of Concept Study of the Combination of ACP196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma $23,276 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.